Navigation Links
Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29

Company to Proceed with Development Program for Oral Compounds to Treat Alcohol Dependence

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) today announced positive preliminary results from a clinical trial of ALKS 29 in alcohol dependent patients. Based on these results, the company plans to move forward with its development program for oral product candidates to treat alcohol dependence. ALKS 29 is a combination of two agents with distinct pharmacologic properties designed to provide advantages over current oral medications for the treatment of alcohol dependence. In the study, ALKS 29 was generally well tolerated and led to both a statistically significant increase in the percent of days abstinent and a decrease in drinking compared to placebo when combined with psychosocial therapy.

"We are encouraged by the positive results from this initial proof of concept study, which provide further rationale for the continued expansion of our addiction franchise," stated Elliot Ehrich, chief medical officer of Alkermes. "Addiction is an underserved disease area where a variety of treatments are needed that can improve outcomes for patients. We look forward to the complete analysis of these data, as we believe insights from this study could help pave the way for the development of ALKS 29 and other proprietary oral compounds for the treatment of alcohol dependence."

In the phase 1/2 study, patients treated with ALKS 29 demonstrated statistically significant improvement compared to placebo in terms of percent of days abstinent, percent of heavy drinking days, and average number of drinks per day. ALKS 29 was generally well tolerated during the study.

The phase 1/2 multi-center, randomized, double-blind, placebo-controlled, eight-week study was designed to assess the efficacy and safety of ALKS 29 in approximately 150 alcohol dependent patients. The study e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
(Date:12/19/2014)...  RESMED INC. (NYSE: RMD ) today announced ... 2015 results on Thursday, January 22, 2015, after the New ... results will be issued after 1:00 p.m. US Pacific Time ... results and future outlook. The earnings call is ... the live webcast of the call can be accessed on ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... AUSTIN, Texas, April 8, 2011 Hanger Orthopedic Group, Inc. (NYSE: ... its results of operations for the quarter ended March 31, 2011, ... issue a press release announcing the results for the quarter ended ... of the market. A conference call to discuss these results is ...
... DENVER, April 8, 2011 At the ... Annual Meeting, April 9-13 at the Colorado ... characteristics of Leksell Gamma Knife® Perfexion™ that ... These include its dedication to intracranial cases, ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces First Quarter 2011 Earnings Release Conference Call 2Elekta Emphasizes Advantages of Leksell Gamma Knife Perfexion Over Competing Systems at 2011 AANS Meeting 2Elekta Emphasizes Advantages of Leksell Gamma Knife Perfexion Over Competing Systems at 2011 AANS Meeting 3
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... LYMAN, S.C., Sept. 11 Southern Home Medical,Equipment, Inc. ... the month of August 2008 compared to July 2008., ... stated, "On the heels of,reporting record sales in the ... on a path of strong sales momentum. Encore Medical ...
... against women in a family also has serious consequences ... sling Monemi from Uppsala University has studied women and ... other things, that children whose mothers are exposed to ... other children. , Kajsa sling Monemi, paediatrician, the ...
... - For Non-US Healthcare Media, - Global ... Improved Survival Outcomes With Vetmedin(R) (pimobendan), Veterinarians and ... promise of an extended happy life together for millions ... that dogs,suffering from the most common type of heart ...
... Residents to Eat Right, Move More ... and Milk Their Diets, BOSTON, Sept. 11 ... fad diets -- which seem to go in and out of,fashion like shoulder ... -- including 51 percent of Massachusetts,residents -- remain overweight or obese., A ...
... 11 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ), ... of products based upon the Microcyn(R),Technology platform, today announced ... exclusive interview on WallSt.net,s 3-Minute Press Show., The ... the,significance of the company,s latest press release., ...
... Plastic surgeon offers the surprise scoop, NEW ... time and an,active lifestyle can impact a person,s ... million Americans turned to cosmetic procedures last,year to ... Shirley Madhere, M.D., says you can improve your ...
Cached Medicine News:Health News:Southern Home Medical Announces Revenues Up 172% for the Month of August 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 3Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 4Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:[video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.net's 3-Minute Press Show 2Health News:Insider Secrets for Beautiful Skin 2
... RELISA ENA Multiparameter Kit is ... for six of the most ... a unique quality control system. ... Check) well in each strip ...
... RELISA ENA assays were designed with the ... clinician in the diagnosis of autoimmune disease. ... disease and 1,000 normal individuals were tested ... Test System. Immuno Concepts compared the results ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Medicine Products: